Document library
Testimony, research and source documents referenced in our work. Each entry says what the document is and where it comes from, so you can read the original for yourself.
FDA advisory committee, June 28, 2022
Public comment by Eric Feintuch, D.C.
Three-minute comment during the open public hearing of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). FDA's official recording, starting at 5:18:05.
Committee vote on an Omicron component for COVID-19 boosters
The committee voted 19-2 in favor. Votes are read individually, including Dr. Paul Offit's "no." FDA's official recording, starting at 8:16:32.
Dr. Paul Offit's remarks before the vote
Called on first when committee discussion opened. He notes that current vaccines still protect against serious illness, questions whether a 1.75-fold rise in neutralizing antibodies is clinically meaningful, points out that BA.4 and BA.5 were by then about half of circulating strains, and argues an updated vaccine should be held to the standard of a new product. FDA's official recording, starting at 6:33:10.
He also asked a question earlier in the day about whether one bivalent vaccine could serve both first doses and boosters (3:58:15).
Slides from the public comment
The slide deck presented with the comment above. Download the PowerPoint file.
Exhibits
Exhibit 1: Evidence of cGMP/cGxP non-compliance
A review of manufacturing compliance in the production and distribution of COVID-19 vaccines, with its table of contents, attachments and the regulations it cites.
cGMP evidence summary (Latypova, TrialSite News, 2022)
Our summary of a published analysis of batch variability, FDA inspection findings, unit-dose testing and serialization, with links to the original article and the FDA records it cites.
Research papers
Towards the emergence of a new form of the neurodegenerative Creutzfeldt-Jakob disease: twenty six cases of CJD declared a few days after a COVID-19 "vaccine" jab
Jean Claude Perez, Claire Moret-Chalmin and Luc Montagnier (Nobel Prize in Physiology or Medicine, 2008). A case series of 26 CJD cases with onset shortly after COVID-19 vaccination, and an analysis of a prion-like region in the spike protein. Preprint posted on ResearchGate; not peer reviewed. DOI 10.13140/RG.2.2.14427.03366.
Prion infections and anti-PrP antibodies trigger converging neurotoxic pathways
Herrmann, Sonati, Falsig et al., Aguzzi lab. A laboratory study showing that prion infection and certain antibodies against the prion protein damage nerve tissue through shared pathways. Background on prion disease mechanisms. Peer reviewed, PLoS Pathogens. DOI 10.1371/journal.ppat.1004662.